Ticker: AGEN

Quick take - Agenus Inc. (NASDAQ: AGEN) Agenus reported Q2 / six‑month 2025 results showing meaningful non‑cash royalty revenue but continuing large operating losses, shrinking cash on hand and heavy royalty/debt liabilities. Management expects near‑term cash inflows from a pending Zydus transact...

Agenus Inc. (NASDAQ: AGEN) has recently released its quarterly report for the period ending March 31, 2025. The company focuses on developing therapies to activate the immune system against cancer and infections, primarily within the immuno-oncology space. Key Financial Highlights: Revenue: $24....